Spyre Therapeutics reported earnings of -$ 0.94 per SYRE share on Nov 3, 2026, beating analysts' expectations by
| Report Date | Nov 3, 2026 |
|---|---|
| Forecasted EPS | -$ 0.82 |
| Earnings Per Share (Surprise) | -$ 0.94 (-$ 0.12) |
| Last Year's EPS | -$ 0.52 |
| EPS YoY Change |
Out of the last 55 earnings reporting periods, Spyre Therapeutics beat analysts’ expectations 12 times and fell short of expectations 13 time(s). Spyre Therapeutics reported earnings per share of -$ 0.94 in the last report falling to reach an estimated EPS of -$ 0.82 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 3, 2026 | -$ 0.82 | -$ 0.94 | -$ 0.15 | |
| Aug 4, 2026 | -$ 0.76 | -$ 0.36 | -$ 0.49 | |
| May 5, 2026 | -$ 0.66 | -$ 0.74 | -$ 0.74 | |
| Feb 19, 2026 | -$ 0.66 | -$ 0.70 | -$ 0.81 | |
| Nov 4, 2025 | -$ 0.76 | -$ 0.15 | -$ 0.81 | |
| Aug 5, 2025 | -$ 0.73 | -$ 0.49 | -$ 1.36 | |
| May 8, 2025 | -$ 0.84 | -$ 0.74 | -$ 0.86 | |
| Feb 28, 2025 | -$ 0.89 | -$ 0.81 | -$ 1.20 | |
| Feb 27, 2025 | -$ 0.89 | -$ 0.81 | -$ 4.05 | |
| Nov 7, 2024 | -$ 0.80 | -$ 1.36 | -$ 9.34 | |
| Aug 7, 2024 | -$ 0.90 | -$ 0.86 | -$ 0.57 | |
| May 9, 2024 | -$ 0.90 | -$ 1.20 | -$ 5.00 | |
| Feb 29, 2024 | -$ 0.48 | -$ 4.05 | -$ 4.89 | |
| Nov 9, 2023 | -$ 0.84 | -$ 9.34 | -$ 5.00 | |
| Aug 11, 2023 | -$ 0.03 | -$ 0.57 | -$ 7.20 | |
| May 11, 2023 | -$ 4.50 | -$ 5.00 | -$ 4.33 | |
| Mar 31, 2023 | -$ 4.50 | -$ 4.89 | -$ 4.84 | |
| Mar 2, 2023 | -$ 5.71 | -$ 5.00 | -$ 6.75 | |
| Dec 30, 2022 | -$ 5.71 | -$ 7.20 | -$ 6.79 | |
| Nov 3, 2022 | -$ 6.25 | -$ 4.33 | -$ 9.25 |
Spyre Therapeutics’s stock was trading at $ 95.51 on Nov 2, 2026 a day before the last earnings report was released.Following the release of the earnings report, SYRE’s price increased to $ 99.04 on Nov 4, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 3, 2026 | -$ 0.94 | $ 95.51 | $ 99.04 | |
| Aug 4, 2026 | -$ 0.36 | $ 94.93 | $ 104.35 | |
| May 5, 2026 | -$ 0.74 | $ 69.13 | $ 73.00 | |
| Feb 19, 2026 | -$ 0.70 | $ 36.60 | $ 43.21 | |
| Nov 4, 2025 | -$ 0.15 | $ 23.78 | $ 22.85 | |
| Aug 5, 2025 | -$ 0.49 | $ 16.16 | $ 15.96 | |
| May 8, 2025 | -$ 0.74 | $ 12.71 | $ 14.10 | |
| Feb 28, 2025 | -$ 0.81 | $ 18.37 | $ 17.94 | |
| Feb 27, 2025 | -$ 0.81 | $ 19.00 | $ 19.70 | |
| Nov 7, 2024 | -$ 1.36 | $ 37.48 | $ 39.58 | |
| Aug 7, 2024 | -$ 0.86 | $ 26.04 | $ 25.25 | |
| May 9, 2024 | -$ 1.20 | $ 33.02 | $ 36.93 | |
| Feb 29, 2024 | -$ 4.05 | $ 26.10 | $ 29.90 | |
| Nov 9, 2023 | -$ 9.34 | $ 9.70 | $ 9.49 | |
| Aug 11, 2023 | -$ 0.57 | $ 13.13 | $ 11.78 | |
| May 11, 2023 | -$ 5.00 | $ 4.10 | $ 3.83 | |
| Mar 31, 2023 | -$ 4.89 | $ 7.28 | $ 7.13 | |
| Mar 2, 2023 | -$ 5.00 | $ 9.88 | $ 9.85 | |
| Dec 30, 2022 | -$ 7.20 | $ 8.93 | $ 10.53 | |
| Nov 3, 2022 | -$ 4.33 | $ 30.50 | $ 27.75 |
Spyre Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Spyre Therapeutics missed analysts’ expectations during the last earnings period by
